Key result
CO2 angiography-guided uRDN safely reduces antihypertensives from 5 to 3 in CKD.
Why the study?
Carbon dioxide angiography may provide a safer alternative for renal artery visualization in patients with refractory hypertension and CKD due to concerns about contrast-induced injury.
Does carbon dioxide angiography-guided ultrasound renal denervation safely improve blood pressure control in patients with refractory hypertension and chronic kidney disease?
Case Report (n=1)
Does carbon dioxide angiography-guided ultrasound renal denervation safely improve blood pressure control in patients with refractory hypertension and chronic kidney disease?
CO2 angiography-guided ultrasound renal denervation is a feasible and safe non-nephrotoxic option for managing refractory hypertension in patients with chronic kidney disease.
May support CO2-guided uRDN for medication reduction in CKD; hypothesis-generating and requires prospective confirmation before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
BAHROU et al. (2025) conducted a case report in Refractory hypertension and chronic kidney disease (n=1). Carbon dioxide angiography-guided ultrasound renal denervation (CO2-guided uRDN) was evaluated on Blood pressure control, medication reduction, and renal function safety. CO2 angiography-guided uRDN safely enabled the reduction of antihypertensives from 5 to 3 agents at 5 weeks without worsening renal function in an 85-year-old man with stage 3a CKD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: